$ALT
Altimmune, Inc.

2015 Q2 Form 10-Q Financial Statement

#000114420415046591 Filed on August 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $1.150M $676.00
YoY Change 170018.34% -59.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.820M $2.420M
YoY Change -24.79% 3.86%
% of Gross Profit
Research & Development $1.223M $2.373M
YoY Change -48.47% -30.27%
% of Gross Profit
Depreciation & Amortization $36.69K $36.21K
YoY Change 1.32% -13.49%
% of Gross Profit
Operating Expenses $3.114M $4.829M
YoY Change -35.5% -16.42%
Operating Profit -$1.965M -$1.170M
YoY Change 67.96% -21.05%
Interest Expense $13.28K $56.55K
YoY Change -76.52% -43.46%
% of Operating Profit
Other Income/Expense, Net -$365.0K $724.1K
YoY Change -150.41% 182.22%
Pretax Income -$2.330M -$445.8K
YoY Change 422.64% -63.61%
Income Tax $11.07K -$10.00K
% Of Pretax Income
Net Earnings -$2.341M -$439.1K
YoY Change 433.1% -64.48%
Net Earnings / Revenue -203.56% -64958.58%
Basic Earnings Per Share -$0.04 -$0.01
Diluted Earnings Per Share -$0.04 -$0.01
COMMON SHARES
Basic Shares Outstanding 63.75M shares 54.48M shares
Diluted Shares Outstanding 63.75M shares

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.40M $11.30M
YoY Change 62.83% -28.48%
Cash & Equivalents $18.41M $11.27M
Short-Term Investments $6.400M $6.400M
Other Short-Term Assets $300.0K $600.0K
YoY Change -50.0% -14.29%
Inventory
Prepaid Expenses
Receivables $1.200M $600.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $19.91M $12.43M
YoY Change 60.1% -42.68%
LONG-TERM ASSETS
Property, Plant & Equipment $308.3K $386.5K
YoY Change -20.25% -15.99%
Goodwill $2.348M $2.348M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.38K $55.03K
YoY Change -2.99% -35.94%
Total Long-Term Assets $2.710M $2.790M
YoY Change -2.86% -3.61%
TOTAL ASSETS
Total Short-Term Assets $19.91M $12.43M
Total Long-Term Assets $2.710M $2.790M
Total Assets $22.62M $15.22M
YoY Change 48.56% -38.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $208.5K $437.4K
YoY Change -52.34% -85.38%
Accrued Expenses $2.700M $1.400M
YoY Change 92.86% -33.33%
Deferred Revenue
YoY Change
Short-Term Debt $200.0K
YoY Change
Long-Term Debt Due $249.5K $1.000M
YoY Change -75.05% 0.0%
Total Short-Term Liabilities $3.300M $2.831M
YoY Change 16.56% -63.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $239.7K
YoY Change -100.0% -80.31%
Other Long-Term Liabilities $900.0K $572.9K
YoY Change 57.11% -0.84%
Total Long-Term Liabilities $900.0K $812.6K
YoY Change 10.76% -54.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.300M $2.831M
Total Long-Term Liabilities $900.0K $812.6K
Total Liabilities $4.300M $4.359M
YoY Change -1.35% -61.65%
SHAREHOLDERS EQUITY
Retained Earnings -$213.0M
YoY Change 5.48%
Common Stock $224.1M
YoY Change 4.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.30M $10.86M
YoY Change
Total Liabilities & Shareholders Equity $22.60M $15.22M
YoY Change 48.45% -38.08%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$2.341M -$439.1K
YoY Change 433.1% -64.48%
Depreciation, Depletion And Amortization $36.69K $36.21K
YoY Change 1.32% -13.49%
Cash From Operating Activities $2.650M -$540.0K
YoY Change -590.74% 10.2%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$40.00K
YoY Change -50.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$20.00K -$40.00K
YoY Change -50.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 2.300M
YoY Change -97.83% -33.53%
NET CHANGE
Cash From Operating Activities 2.650M -540.0K
Cash From Investing Activities -20.00K -40.00K
Cash From Financing Activities 50.00K 2.300M
Net Change In Cash 2.680M 1.720M
YoY Change 55.81% -41.3%
FREE CASH FLOW
Cash From Operating Activities $2.650M -$540.0K
Capital Expenditures -$20.00K -$40.00K
Free Cash Flow $2.670M -$500.0K
YoY Change -634.0% 11.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Assets Current
AssetsCurrent
19905673 USD
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
308256 USD
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53384 USD
CY2015Q2 us-gaap Goodwill
Goodwill
2348453 USD
CY2015Q2 us-gaap Assets
Assets
22615766 USD
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
208456 USD
CY2015Q2 pip Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1904387 USD
CY2015Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
790617 USD
CY2015Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
249491 USD
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64224374 shares
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
316014 USD
CY2014Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
USD
CY2015Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74233 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
70326 USD
CY2015Q2 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
108302 USD
CY2015Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
481747 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18411839 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1222527 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1819241 USD
CY2014Q2 pip Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation
OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation
USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
-229192 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18643351 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-229528 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220283320 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
18274145 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21978241 USD
CY2015Q2 us-gaap Billed Contract Receivables
BilledContractReceivables
387635 USD
CY2014Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
110656 USD
CY2015Q2 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
790185 USD
CY2014Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
297431 USD
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63603303 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63691214 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53861988 shares
us-gaap Contracts Revenue
ContractsRevenue
8218316 USD
us-gaap Contracts Revenue
ContractsRevenue
7401458 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2836154 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5799687 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4015361 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5097361 USD
us-gaap Restructuring Charges
RestructuringCharges
2096791 USD
us-gaap Restructuring Charges
RestructuringCharges
USD
us-gaap Depreciation
Depreciation
73793 USD
us-gaap Depreciation
Depreciation
76147 USD
us-gaap Operating Expenses
OperatingExpenses
9022099 USD
us-gaap Operating Expenses
OperatingExpenses
10973195 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3571737 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
217630 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1025190 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7285 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1550 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42881 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
897214 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-846664 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2674523 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
30873 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
23037 USD
us-gaap Net Income Loss
NetIncomeLoss
-877537 USD
us-gaap Net Income Loss
NetIncomeLoss
-2697560 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
276979 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1427113 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
4828804 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1169871 USD
CY2014Q2 us-gaap Interest Expense
InterestExpense
56554 USD
CY2014Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
782549 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1912 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
724083 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-445788 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
492754 USD
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
1149570 USD
CY2015Q2 us-gaap Restructuring Charges
RestructuringCharges
35982 USD
CY2015Q2 us-gaap Depreciation
Depreciation
36687 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3114437 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1964867 USD
CY2015Q2 us-gaap Interest Expense
InterestExpense
13279 USD
CY2015Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-120615 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1911 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-364997 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2329864 USD
CY2015Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
11068 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2340932 USD
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63745834 shares
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
3658933 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2372687 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2419909 USD
CY2014Q2 us-gaap Restructuring Charges
RestructuringCharges
USD
CY2014Q2 us-gaap Depreciation
Depreciation
36208 USD
CY2014Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-6668 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-439120 USD
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54670870 shares
CY2015Q2 pip Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation
OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation
229192 USD
pip Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation
OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation
229192 USD
pip Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation
OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation
USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
336 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1293 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-648009 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2698853 USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1410 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-636 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2113150 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-439756 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
-229192 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
USD
us-gaap Share Based Compensation
ShareBasedCompensation
333231 USD
us-gaap Share Based Compensation
ShareBasedCompensation
891983 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
30873 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
23037 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
17879 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
49311 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7600 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5393 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-1582129 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
127433 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
278333 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-182940 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
891983 USD
CY2015Q2 pip Billed And Unbilled Accounts Receivable Net
BilledAndUnbilledAccountsReceivableNet
1200000 USD
CY2015Q2 pip Additional Common Stock Aggregate Gross Sales
AdditionalCommonStockAggregateGrossSales
3000000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1116 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-231512 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
784103 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10480979 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11265082 USD
us-gaap Interest Paid
InterestPaid
21452 USD
us-gaap Interest Paid
InterestPaid
77797 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
333231 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-690790 USD
us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
790617 USD
us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
647233 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1838131 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-341723 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60055 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2827400 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56277 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79227 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7600 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48677 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71227 USD
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-499998 USD
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-499998 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1091740 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
376545 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5275584 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-123453 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3683846 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
673 USD
CY2015Q1 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2000000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
12000 shares
pip Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod
117500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1357755 shares
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
900000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12400000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Use of Estimates</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></p> </div>
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
133604 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
363105 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
140000 shares
CY2014Q2 pip Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod
shares
CY2015Q2 us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
-1100000 USD
pip Share Based Compensation Extension Of Exercise Period
ShareBasedCompensationExtensionOfExercisePeriod
75000 USD
pip Share Based Compensation Reversal From Stock Option Forfeitures
ShareBasedCompensationReversalFromStockOptionForfeitures
129000 USD
pip Share Based Compensation Reversal Net
ShareBasedCompensationReversalNet
54000 USD
CY2015Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
590049 USD
CY2015Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1922781 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5620128 shares
CY2009Q3 pip Warrant Expiration Date
WarrantExpirationDate
2015-01-28
CY2015Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
113000000 USD
CY2015Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
194600000 USD
CY2015Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
113100000 USD
CY2015Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
81500000 USD
CY2015Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
250009 USD
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
PHARMATHENE, INC
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Trading Symbol
TradingSymbol
PIP
dei Entity Central Index Key
EntityCentralIndexKey
0001326190
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q

Files In Submission

Name View Source Status
0001144204-15-046591-index-headers.html Edgar Link pending
0001144204-15-046591-index.html Edgar Link pending
0001144204-15-046591.txt Edgar Link pending
0001144204-15-046591-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pip-20150630.xml Edgar Link completed
pip-20150630.xsd Edgar Link pending
pip-20150630_cal.xml Edgar Link unprocessable
pip-20150630_def.xml Edgar Link unprocessable
pip-20150630_lab.xml Edgar Link unprocessable
pip-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v416176_10q.htm Edgar Link pending
v416176_ex31-1.htm Edgar Link pending
v416176_ex31-2.htm Edgar Link pending
v416176_ex32-1.htm Edgar Link pending
v416176_ex32-2.htm Edgar Link pending